For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
People with excess body fat who build and keep muscle may be less likely to develop obesity-induced heart, liver, or kidney damage or die early, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Despite clear evidence that excess body fat can directly cause illness, obesity is often viewed as a risk...
A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society. The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders. “Early...
As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as semaglutide (Ozempic, Wegovy) — gain traction for treating diabetes and promoting weight loss, a new concern is emerging: Are older adults at risk of losing too much muscle? An editorial in Annals of Internal Medicine warns that these popular drugs may exacerbate sarcopenia — the...
As part of the ENDO 2025 session, “Obesity Management Across the Lifespan: Special Considerations,” Lisa Morselli, MD, PhD, talks about the unique challenges in obesity management in women during their reproductive years. On Tuesday, July 15, ENDO 2025 here in San Francisco will feature a session titled, “Obesity Management Across the Lifespan: Special Considerations.” As...
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. Testosterone not only plays a critical role in the body when it comes to male sexual...
For the eleventh year running, Endocrine News talks to editors from Endocrine Society publications to unearth the most impressive breakthroughs in endocrine science and research for 2025. From GLP-1s, adrenal treatments, and acromegaly breakthroughs to obesity, diabetes, and cutting-edge research in reproductive medicine, 2025 was a banner year for endocrine research and researchers! For more...
New research reveals long-term bone health implications Research presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on...
As part of the ENDO 2025 session, “Obesity Management Across the Lifespan: Special Considerations,” Lisa Morselli, MD, PhD, talks about the unique challenges in obesity management in women during their reproductive years. On Tuesday, July 15, ENDO 2025 here in San Francisco will feature a session titled, “Obesity Management Across the Lifespan: Special Considerations.” As...
